Profusa, Inc. Common Stock (PFSA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Profusa, Inc. Common Stock (PFSA) has a cash flow conversion efficiency ratio of 0.091x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.58 Million) by net assets ($-28.20 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of Profusa, Inc. Common Stock to measure how much of total assets are equity-financed.
Profusa, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how Profusa, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check how high is Profusa, Inc. Common Stock's earnings quality to evaluate the quality of earnings relative to operating cash generation.
Profusa, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Profusa, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Volvere PLC
LSE:VLE
|
0.004x |
|
GAMES BOX S.A. ZY-10
F:ZN6
|
-0.018x |
|
Watkin Jones PLC
LSE:WJG
|
-0.050x |
|
Goldflare Exploration Inc
V:GOFL
|
-0.052x |
|
Splash Beverage Group Inc
NYSE MKT:SBEV
|
0.184x |
|
Hanstone Gold Corp
V:HANS
|
0.486x |
|
MCS Services Ltd
AU:MSG
|
-0.350x |
|
Time Finance PLC
LSE:TIME
|
-0.009x |
Annual Cash Flow Conversion Efficiency for Profusa, Inc. Common Stock (2021–2025)
The table below shows the annual cash flow conversion efficiency of Profusa, Inc. Common Stock from 2021 to 2025. For the full company profile with market capitalisation and key ratios, see Profusa, Inc. Common Stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-26.66 Million | $-16.25 Million | 0.609x | +3416.71% |
| 2024-12-31 | $-119.20 Million | $-2.07 Million | 0.017x | -56.69% |
| 2023-12-31 | $-110.00 Million | $-4.40 Million | 0.040x | -48.16% |
| 2022-12-31 | $-99.77 Million | $-7.70 Million | 0.077x | -39.59% |
| 2021-12-31 | $-83.66 Million | $-10.69 Million | 0.128x | -- |
About Profusa, Inc. Common Stock
Profusa, Inc., a digital health technology company, develops bioengineered sensors for body to detect and continuously transmit clinical-grade data for personal and medical use in the United States. It offers the Lumee Oxygen Platform to monitor compromised tissue for peripheral artery disease, chronic wounds, and reconstructive surgery. The company researches and develops the Lumee Glucose Platf… Read more